Application of circulating tfpi-2 (tissue factor pathway inhibitor 2) in the assessment of atrial fibrillation and anticoagulation therapy

A TFPI-2, atrial fibrillation technology, used in disease diagnosis, instrumentation, biomaterial analysis, etc., can solve problems such as cessation

Pending Publication Date: 2021-08-24
F HOFFMANN LA ROCHE & CO AG +2
View PDF8 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although episodes can last up to 7 days in such patients, in most cases of paroxysmal AF the episodes will cease in less than 24 hours

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of circulating tfpi-2 (tissue factor pathway inhibitor 2) in the assessment of atrial fibrillation and anticoagulation therapy
  • Application of circulating tfpi-2 (tissue factor pathway inhibitor 2) in the assessment of atrial fibrillation and anticoagulation therapy
  • Application of circulating tfpi-2 (tissue factor pathway inhibitor 2) in the assessment of atrial fibrillation and anticoagulation therapy

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0395] Example 1: Differential expression of TFPI-2 in cardiac tissues of AF patients

[0396] Differential TFPI-2 expression levels have been determined in myocardial tissue samples from the right atrial appendage of n=38 patients.

[0397] RNAseq analysis

[0398] Atrial tissue was sampled during open thoracotomy due to CABG or valve surgery. Evidence of AF or SR (control) was generated by simultaneous endocardial-epicardial hyperintensity activation mapping during surgery. AF patients and controls were matched for sex, age, and comorbidities.

[0399] Atrial tissue samples are prepared for

[0400] AF patients; n=9 patients

[0401] • Control patients in SR; n=29 patients.

[0402] Differential expression of TFPI-2 was determined in RNAseq analysis using algorithms RSEM and DESeq2.

[0403] like figure 1 As shown, TFPI-2 expression was found to be upregulated in the atrial tissues of the 9 paroxysmal AF patients analyzed compared with 29 control patients.

[0404] T...

example 2

[0407] Example 2: Assessment of AF with cyclic TFPI-2

[0408] The MAPPING study involved patients undergoing thoracotomy. Samples were obtained prior to anesthesia and surgery. Patients were electrophysiologically characterized using high-density epicardial mapping (high-density mapping) with a multielectrode array.

[0409] Circulating TFPI-2 levels have been determined in 12 patients with paroxysmal atrial fibrillation, 16 patients with persistent atrial fibrillation, and 30 control patients for optimal (age, sex, comorbidities) matching. TFPI-2 was determined in samples from the MAPPING study.

[0410] Measurements were performed in 30 patients in sinus rhythm (SR), 12 patients with paroxysmal atrial fibrillation (parAF) and 16 patients with persistent atrial fibrillation (persAF).

[0411] Figure 2a showed that compared with SR patients, TFPI-2 was significantly elevated in persAF patients (AUC0.71). Therefore, TFPI-2 can be used to diagnose persAF. Elevated TFPI-2...

example 3

[0415] Example 3: Prediction of stroke

[0416] Analytical method

[0417] The ability of circulating TFPI-2 to predict the risk of stroke was assessed in a prospective multicenter registry of patients with documented atrial fibrillation (Conen D., Forum Med Suisse 2012; 12:860-862). TFPI-2 was measured using a stratified case cohort design as described by Borgan (2000).

[0418] For each of the 70 patients who experienced a stroke ("event") during follow-up, 1 matched control patient was selected. Control patients were matched on the basis of demographic and clinical information on age, sex, history of hypertension, type of atrial fibrillation, and history of heart failure (CHF history).

[0419] TFPI-2, NTproBNP, ESM-1, Ang-2, IGFBP-7 results were available for 67 event-experienced patients and 66 event-naive patients.

[0420] TFPI-2 was measured using the Olink platform, therefore no absolute concentration values ​​are available and can be reported. Results will be rep...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of TFPI-2 in a sample from the subject, and comparing the amount of TFPI-2 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for assessing anticoagulation therapy and to methods for predicting the risk of stroke of a subject. Said methods are based on the determination of the amount of TFPI-2 in a sample from the subject.

Description

technical field [0001] The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of: determining the amount of TFPI-2 in a sample from the subject, and comparing the amount of TFPI-2 with a reference amount , to assess atrial fibrillation. Furthermore, the present invention relates to methods for assessing anticoagulation therapy and methods for predicting a subject's risk of stroke. The method is based on the determination of the amount of TFPI-2 in a sample from a subject. Background technique [0002] Atrial fibrillation (AF) is the most common type of cardiac arrhythmia and one of the most prevalent disorders in the elderly population. Atrial fibrillation is characterized by irregular heart beats and usually begins with a brief abnormal beat that increases over time and can become a permanent condition. An estimated 2.7-6.1 million Americans have atrial fibrillation, and approximately 33 million people w...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/68
CPCG01N33/6893G01N2333/8114G01N2800/2871G01N2800/326G01N2800/52G01N2333/58G01N2333/515G01N2333/4745G01N2496/00G01N2800/50
Inventor P·卡斯特纳A·齐格勒U-H·维恩胡斯-特伦V·罗尼M·迪特里克U·肖滕
Owner F HOFFMANN LA ROCHE & CO AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap